We've been anticipating this study for a looooooong time, but it's finally here. It's probably good to review past OD Central posts about cross-linking, so here goes: September 2011: Avedro gets FDA approval for orphan drug status for CXL for KCN treatment. December 2011: Avedro gets FDA approval for orphan drug status for CXL for post-LASIK ectasia treatment. January 2012: Avedro gets European CE approval for LASIK Xtra, a procedure combining LASIK and CXL. January 2012: Avedro gets Canadian approval for LASIK Xtra. March 2012: Avedro submits New Drug Application to FDA. April 2012: Avedro announces it's newly-approved FDA study to compare CXL efficacy as a treatment for KCN. June 2012: Avedro is making improvements to its Riboflavin Ophthalmic Solution to allow for faster corneal penetration. - jw |